Overview

  • Product nameAnti-FAK (phospho Y576) antibody
    See all FAK primary antibodies
  • Description
    Rabbit polyclonal to FAK (phospho Y576)
  • SpecificityThis antibody detects endogenous levels of FAK only when phosphorylated at tyrosine 576.
  • Tested applicationsSuitable for: IHC-P, ELISA, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthesized phosphopeptide derived from human FAK around the phosphorylation site of tyrosine 576 (S-T-YP-Y-K).

  • Positive control
    • WB: Extracts from NIH/3T3 cells IHC-P: human brain tissue.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab55335 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.
ELISA 1/5000.
WB Use at an assay dependent concentration. Detects a band of approximately 116 kDa (predicted molecular weight: 119 kDa).

Target

  • FunctionNon-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly. Plays a potential role in oncogenic transformations resulting in increased kinase activity.
  • Tissue specificityExpressed in all organs tested, in lymphoid cell lines, but most abundantly in brain.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. FAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
  • DomainThe first Pro-rich domain interacts with the SH3 domain of CRK-associated substrate (BCAR1) and CASL.
    The carboxy-terminal region is the site of focal adhesion targeting (FAT) sequence which mediates the localization of FAK1 to focal adhesions.
  • Post-translational
    modifications
    Phosphorylated on 6 tyrosine residues upon activation. Microtubule-induced dephosphorylation at Tyr-397 could be catalyzed by PTPN11 and regulated by ZFYVE21. Dephosphorylated by PTPN11 upon EPHA2 activation by its ligand EFNA1.
  • Cellular localizationCell junction > focal adhesion. Cell membrane. Constituent of focal adhesions.
  • Information by UniProt
  • Database links
  • Alternative names
    • FADK 1 antibody
    • FADK antibody
    • FAK related non kinase polypeptide antibody
    • FAK1 antibody
    • FAK1_HUMAN antibody
    • Focal adhesion kinase 1 antibody
    • Focal adhesion Kinase antibody
    • Focal adhesion kinase isoform FAK Del33 antibody
    • Focal adhesion kinase related nonkinase antibody
    • FRNK antibody
    • p125FAK antibody
    • pp125FAK antibody
    • PPP1R71 antibody
    • Protein phosphatase 1 regulatory subunit 71 antibody
    • Protein tyrosine kinase 2 antibody
    • Protein-tyrosine kinase 2 antibody
    • Ptk2 antibody
    • PTK2 protein tyrosine kinase 2 antibody
    see all

Anti-FAK (phospho Y576) antibody images

  • ab55335, at 1/50 dilution, staiing FAK in paraffin embedded human brain tissue by Immunohistochemsitry in the absence (left image) or presence (right image) of the immunising phosphopeptide.
  • All lanes : Anti-FAK (phospho Y576) antibody (ab55335) at 1/500 dilution

    Lane 1 : Extracts from NIH/3T3 cells
    Lane 2 : Extracts from NIH/3T3 cells with the immunising phosphopeptide.


    Predicted band size : 119 kDa
    Observed band size : 116 kDa (why is the actual band size different from the predicted?)

References for Anti-FAK (phospho Y576) antibody (ab55335)

This product has been referenced in:
  • Herold CI  et al. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 17:6061-70 (2011). IHC-P ; Human . Read more (PubMed: 21810917) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab55335.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"